Navigation Links
Gene Vaccine Protects Mice Against Development Of Her2/neu Breast Cancer

Based on successful animal studies, a novel vaccine that uses immune cells as factories to produce Her2/neu protein may offer a way to treat some human breast cancers, say researchers at The University of Texas M. D. Anderson Cancer Center. [Ed : Her2/neu is a protein often present / surexpressed in breast cancer] Their study, published in the online journal, Breast Cancer Research, on Nov. 29, 2004, showed that the vaccine protected 86 percent of experimental mice against HER2/neu-associated breast cancer, even though the tumors were implanted directly into mice.

“This is an exciting strategy that seems to elicit a complete immunologic response against HER2/neu,?says the study’s lead author, Lawrence Lachman, Ph.D., a professor in the Department of Experimental Therapeutics. “Now that we have gone as far as we can in animal studies, I hope this agent might be tested clinically both to treat HER2/neu breast tumors, and to prevent them from spreading.?Up to one-third of human breast cancers are associated with over-expression of the HER2/neu cell surface receptor protein, which continuously “tells?the cancer cell to grow, this producing an aggressive disease that is difficult to stop. The drug Herceptin treats this kind of breast cancer by “plugging?these receptors with a monoclonal antibody, but this treatment “produces only a passive and transitory immune reaction,?Lachman said. “This vaccine, however, like many that treat microbial infections, appears to create a memory in the immune system that produces a lasting protective response.?The vaccine used in this study is a “viral-vectored?approach, in which a naturally occurring virus is re-engineered to be propagation defective but still able to function as a delivery system for proteins from the cancer cells that are to be targeted by the animal’s immune system. The basis for this new va
'"/>

Source:M.D. Anderson Cancer Center


Page: 1 2 3

Related biology news :

1. FDA Approves Human Hookworm Vaccine for Phase I Safety Trials
2. Live Recombinant Adenovirus Vaccine Technique Explored
3. NIAID Initiates Trial of Experimental Avian Flu Vaccine
4. Study Models Impact Of Anthrax Vaccine
5. New Insights Into HIV Immunity Suggest Alternative Approach to Vaccines
6. Pathogen-Mimicking Vaccine As Strategy For Cancer Therapy
7. EuroVacc 02 HIV Vaccine Trial Begins
8. Active Vaccine Prevents Mice From Developing Prion Disease
9. New Vaccine To Be Used For First Time In Polio Outbreak Response
10. Boosting The BCG Vaccine To Beat Tuberculosis
11. Visceral Leishmaniasis: Successful Vaccine Trial In Dogs
Post Your Comments:
(Date:12/22/2014)... 2014 Holiday Season may be the brightest ever for ... the long anticipated floodgates for consumer biometrics may finally ... phones, tablets, and wearable mobile devices that incorporate biometrics ... with nearly 4.8 billion biometric devices by 2020.   ...
(Date:12/19/2014)... Dec. 18, 2014   LaunchKey , the first decentralized ... and Internet of Things era, today announced the close ... round was led by Metamorphic Ventures with participation from ... VegasTechFund, and others.  LaunchKey has raised $4 million to ...
(Date:12/17/2014)... , Dec. 16, 2014 Valencell, a leader in ... biometric technology to industry leaders such as Intel, Jabra, ... validated, biometric wearable products. These products will be showcased ... Las Vegas . "Our ...
Breaking Biology News(10 mins):First Season of Holiday Shopping with Mobile Biometric Payments Wraps Up With a Present for Biometrics Industry: A Rosy Forecast for More Than 2 Billion Users of 4.8 Billion Mobile Biometric Devices by 2020 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2
... immune system defects, visual pathologies, heart disease. A ... providing an excellent model system to unravel these ... worldwide are currently working with this organism and ... health; Spain is among the leading countries for ...
... more open to the idea of "designing" babies than the ... the University of East Anglia. , The findings will be ... Science on Setpember 5. , Dr. Hampton and his team ... what different groups of people in the UK would "design ...
... discovered on an unexplored mountain range in northern ... Conservation Programme. It was named "Yariguies Brush-Finch," with ... The new brush-finch was described by an Anglo-Colombian ... and Blanca Huertas (Natural History Museum and University ...
Cached Biology News:A valuable fly for research into disease 2Designer babies - what would you do for a 'healthy' baby? 2New bird discovered on unexplored Columbian mountain 2
(Date:1/22/2015)... , Nueva Jersey , 22 de enero ... for Biomedical Research abre hoy su llamada a nominaciones ... cuya investigación científica ha hecho, o tiene el potencial ... salud humana. Las nominaciones se aceptarán hasta el 15 ...
(Date:1/22/2015)... PRINCETON, N.J. , Jan. 22, 2015  Derma ... tissue regeneration company focused on advanced wound care, ... from placental tissues, have been added to the ... announcement increases the opportunity for the AMNIOEXCEL® and ...
(Date:12/24/2014)... , Dec. 24, 2014  Vermillion, Inc. (Nasdaq:   ... disease, announced today that the Company closed its ... Investment Management, Jack W. Schuler , Birchview ... were $10.5 million, before offering expenses.  The proceeds ...
(Date:12/24/2014)... 2014 Earlier this year in a June ... the Adult Stem Cell Technology Center, LLC ( ASCTC ) ... property of adult tissue stem cells. His title “Asymmetric ... for the Future,” embodied the essence of his message to ...
Breaking Biology Technology:El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4
... question regarding man,s existence has been left unanswered by ... homosexuals don,t naturally reproduce, their gene pool is not ... survival and existence?  What if their existence served a ... we,re to believe Darwin,s laws of evolution, the mere ...
... Mass., June 14, 2011 Sensitech,s TempTale®4 (TT4) ... advanced and flexible range of configurable alarm options ... global supply chain by allowing for more precise, ... design gives users the ability to program up ...
... Merriman Capital, Inc., a wholly ... MERR ), today announced that it will serve as ... (ASX: CIR; OTCQX: CKDXY) as it begins trading on ... Circadian is an Australian biotechnology company developing innovative, ...
Cached Biology Technology:Sensitech® Inc.'s TempTale®4 Multi-Alarm Temperature Monitors Offer Highly Advanced and Flexible Range of Configurable Alarm Options 2Sensitech® Inc.'s TempTale®4 Multi-Alarm Temperature Monitors Offer Highly Advanced and Flexible Range of Configurable Alarm Options 3Merriman Capital Announces Sponsorship of Circadian Technologies on OTCQX 2Merriman Capital Announces Sponsorship of Circadian Technologies on OTCQX 3
... ultimate in utility and flexibility press-to-seal silicone ... needs of the researcher. They are available ... as sheet material that can be easily ... are autoclavable and non-cytotoxic and can be ...
Argon Calibration Source...
SHEEP ANTI ESCHERICHIA COLI...
Recombinant Rat Leptin, CF...
Biology Products: